Expression of Elongation Factor-2 Kinase Contributes to Anoikis Resistance and Invasion of Human Glioma Cells

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2011 Feb 1

PMID 21278783

Citations 11

Authors

Li Zhang

Yi Zhang

Xiao-Yuan Liu

Zheng-Hong Qin

Jin-Ming Yang

Affiliations

Soon will be listed here.

Abstract

Aim: To determine whether elongation factor-2 kinase (eEF-2 kinase) contributes to the malignant phenotype of glioblastoma multiforme by promoting the migration and invasion of glioma cells. The mechanism involved was also explored.

Methods: Human glioma cell lines T98G and LN-229 were used. The expression of eEF-2 kinase was silenced using siRNA, and the invasive potential of tumor cells was assessed using a wound-healing assay and a Matrigel invasion assay. Apoptosis was determined using propidium iodide (PI) staining and Western blot analysis of cleaved caspase-3.

Results: Silencing the expression of eEF-2 kinase by siRNA significantly suppressed both the migration and invasion of human glioma cells. Silencing eEF-2 kinase expression also sensitized glioma cells to anoikis, thereby decreasing tumor cell viability in the absence of attachment. Treatment of tumor cells with the caspase inhibitor z-VAD-fmk down-regulated Bim accumulation and abolished glioma cell sensitivity to anoikis.

Conclusion: The results suggest that the expression of eEF-2 kinase contributes to migration and invasion of human glioma cells by protecting them from anoikis. eEF-2 kinase expression may serve as a prognostic marker and a novel target for cancer therapy.

Citing Articles

Forms of Non-Apoptotic Cell Death and Their Role in Gliomas-Presentation of the Current State of Knowledge.

Nafe R, Hattingen E Biomedicines. 2024; 12(7).

PMID: 39062119 PMC: 11274595. DOI: 10.3390/biomedicines12071546.

Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings.

Begagic E, Pugonja R, Beculic H, celikovic A, Tandir Lihic L, Kadic Vukas S Brain Sci. 2023; 13(11).

PMID: 38002561 PMC: 10669565. DOI: 10.3390/brainsci13111602.

Analysis of differential membrane proteins related to matrix stiffness-mediated metformin resistance in hepatocellular carcinoma cells.

Gao X, Qian J, Zhang Y, Wang H, Cui J, Yang Y Proteome Sci. 2023; 21(1):14.

PMID: 37740172 PMC: 10517517. DOI: 10.1186/s12953-023-00216-7.

Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.

Muzyka L, Goff N, Choudhary N, Koltz M Int J Mol Sci. 2023; 24(13).

PMID: 37445633 PMC: 10341773. DOI: 10.3390/ijms241310456.

Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future.

Zhu Z, Fang C, Xu H, Yuan L, Du Y, Ni Y Front Oncol. 2022; 12:976557.

PMID: 36046036 PMC: 9423707. DOI: 10.3389/fonc.2022.976557.

References

Xu C, Chang C . Expression profiles of the genes associated with metabolism and transport of amino acids and their derivatives in rat liver regeneration. Amino Acids. 2007; 34(1):91-102. DOI: 10.1007/s00726-007-0576-2. View

Zinck R, Cahill M, Kracht M, Sachsenmaier C, Hipskind R, Nordheim A . Protein synthesis inhibitors reveal differential regulation of mitogen-activated protein kinase and stress-activated protein kinase pathways that converge on Elk-1. Mol Cell Biol. 1995; 15(9):4930-8. PMC: 230739. DOI: 10.1128/MCB.15.9.4930. View

Collins N, Reginato M, Paulus J, Sgroi D, LaBaer J, Brugge J . G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol. 2005; 25(12):5282-91. PMC: 1140593. DOI: 10.1128/MCB.25.12.5282-5291.2005. View

Salhia B, Tran N, Symons M, Winkles J, Rutka J, Berens M . Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn. 2006; 6(4):613-26. DOI: 10.1586/14737159.6.4.613. View

Arora S, Yang J, Hait W . Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res. 2005; 65(9):3806-10. DOI: 10.1158/0008-5472.CAN-04-4036. View

Ryazanov A, Rudkin B, Spirin A . Regulation of protein synthesis at the elongation stage. New insights into the control of gene expression in eukaryotes. FEBS Lett. 1991; 285(2):170-5. DOI: 10.1016/0014-5793(91)80798-8. View

Kaczmarek L, Surmacz E, Baserga R . Cycloheximide or puromycin can substitute for PDGF in inducing cellular DNA synthesis in quiescent 3T3 cells. Cell Biol Int Rep. 1986; 10(6):455-63. DOI: 10.1016/0309-1651(86)90041-x. View

Parmer T, Ward M, Yurkow E, Vyas V, Kearney T, Hait W . Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer. 1999; 79(1):59-64. PMC: 2362180. DOI: 10.1038/sj.bjc.6690012. View

Cano E, Hazzalin C, Mahadevan L . Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun. Mol Cell Biol. 1994; 14(11):7352-62. PMC: 359270. DOI: 10.1128/mcb.14.11.7352-7362.1994. View

10.

Bagaglio D, Cheng E, Gorelick F, Mitsui K, Nairn A, Hait W . Phosphorylation of elongation factor 2 in normal and malignant rat glial cells. Cancer Res. 1993; 53(10 Suppl):2260-4. View

11.

Connolly E, Braunstein S, Formenti S, Schneider R . Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol. 2006; 26(10):3955-65. PMC: 1489005. DOI: 10.1128/MCB.26.10.3955-3965.2006. View

12.

Herschman H . Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem. 1991; 60:281-319. DOI: 10.1146/annurev.bi.60.070191.001433. View

13.

Giese A, Bjerkvig R, Berens M, Westphal M . Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003; 21(8):1624-36. DOI: 10.1200/JCO.2003.05.063. View

14.

Edwards D, Mahadevan L . Protein synthesis inhibitors differentially superinduce c-fos and c-jun by three distinct mechanisms: lack of evidence for labile repressors. EMBO J. 1992; 11(7):2415-24. PMC: 556716. DOI: 10.1002/j.1460-2075.1992.tb05306.x. View

15.

Serfass L, van Herpen C, Saghatchian M . Molecular targets and cancer therapeutics. Eur J Cancer. 2007; 43(10):1494-5. View

16.

Tan T, Degenhardt K, Nelson D, Beaudoin B, Nieves-Neira W, Bouillet P . Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell. 2005; 7(3):227-38. DOI: 10.1016/j.ccr.2005.02.008. View

17.

Donze O, Jagus R, Koromilas A, Hershey J, Sonenberg N . Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J. 1995; 14(15):3828-34. PMC: 394457. DOI: 10.1002/j.1460-2075.1995.tb00052.x. View

18.

Reginato M, Mills K, Paulus J, Lynch D, Sgroi D, Debnath J . Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol. 2003; 5(8):733-40. DOI: 10.1038/ncb1026. View

19.

Yoeli-Lerner M, Toker A . Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle. 2006; 5(6):603-5. DOI: 10.4161/cc.5.6.2561. View

20.

Nunes P, Calaza K, Albuquerque L, Fragel-Madeira L, Sholl-Franco A, Ventura A . Signal transduction pathways associated with ATP-induced proliferation of cell progenitors in the intact embryonic retina. Int J Dev Neurosci. 2007; 25(8):499-508. DOI: 10.1016/j.ijdevneu.2007.09.007. View